A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Phase of Trial: Phase II/III
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Acronyms BRAVE-AA1
- Sponsors Eli Lilly and Company
- 16 Oct 2019 Planned End Date changed from 30 Mar 2022 to 1 Mar 2022.
- 16 Oct 2019 Planned primary completion date changed from 9 Dec 2020 to 10 Nov 2020.
- 02 Jul 2019 Planned End Date changed from 5 Aug 2022 to 30 Mar 2022.